These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9629319)

  • 21. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.
    Angeli P; Merkel C
    J Hepatol; 2008; 48 Suppl 1():S93-103. PubMed ID: 18304678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of hepatorenal syndrome in liver cirrhosis].
    Yan M; Meng FL
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):458. PubMed ID: 15975285
    [No Abstract]   [Full Text] [Related]  

  • 23. Pathogenesis and outcome of hepatorenal syndrome in patients undergoing orthotopic liver transplant.
    Gonwa TA; Poplawski S; Paulsen W; Brajtbord D; Goldstein R; Husberg B; Klintmalm GB
    Transplantation; 1989 Feb; 47(2):395-7. PubMed ID: 2645724
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of hepatorenal syndrome.
    Kiser TH; Maclaren R; Fish DN
    Pharmacotherapy; 2009 Oct; 29(10):1196-211. PubMed ID: 19792993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activated cytokine pattern in hepatorenal syndrome: fall in levels after successful orthotopic liver transplantation.
    Burke GW; Cirocco R; Roth D; Fernandez J; Allouche M; Markou M; Reddy R; Jeffers L; Schiff E; Nery J
    Transplant Proc; 1993 Apr; 25(2):1876-7. PubMed ID: 8470211
    [No Abstract]   [Full Text] [Related]  

  • 26. Circulatory function and hepatorenal syndrome in cirrhosis.
    Ruiz-del-Arbol L; Monescillo A; Arocena C; Valer P; Ginès P; Moreira V; Milicua JM; Jiménez W; Arroyo V
    Hepatology; 2005 Aug; 42(2):439-47. PubMed ID: 15977202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of ascites in patients with end-stage liver disease.
    Saadeh S; Davis GL
    Rev Gastroenterol Disord; 2004; 4(4):175-85. PubMed ID: 15580152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
    Gentilini P; Laffi G; La Villa G; Raggi VC
    Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical analysis of 38 patients with hepatorenal syndrome].
    Wang Y; Cui Y; Jia JD; Ou XJ; Qian LX; Zhang FK; Yin SS; Zhao XY; Wang BE
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):628. PubMed ID: 14572349
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of HCV-related end-stage liver disease in HIV-coinfected patients.
    Merchante N; Jiménez-Saenz M; Pineda JA
    AIDS Rev; 2007; 9(3):131-9. PubMed ID: 17982938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
    von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
    Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
    Gülberg V; Bilzer M; Gerbes AL
    Hepatology; 1999 Oct; 30(4):870-5. PubMed ID: 10498636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatorenal syndrome.
    Guevara M; Rodés J
    Int J Biochem Cell Biol; 2005 Jan; 37(1):22-6. PubMed ID: 15381144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatorenal syndrome.
    Gattoni A; Marotta F; Vangieri B; Pisani G; Cristiano F
    Clin Ter; 2004 Sep; 155(9):375-89. PubMed ID: 15700631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hepatorenal syndrome: pathogenesis and treatment].
    Ashkenazi E; Ilan Y; Shoval D
    Harefuah; 2007 Jun; 146(6):475-9, 499. PubMed ID: 17760404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of the relationship between hepatorenal syndrome and plasma ammonia].
    He Y; Li GX; Xia Y
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):45-8. PubMed ID: 20128969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
    Testro AG; Wongseelashote S; Angus PW; Gow PJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cox regression analysis of predictive factors of hepatorenal syndrome].
    Zhang WJ; Yang DH; Shu JC
    Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):586-7. PubMed ID: 14572331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.